Cancer Immunology, Immunotherapy

, Volume 41, Issue 5, pp 309–316

Antiproliferative effects of bacillus Calmette-Guérin and interferon α2b on human bladder cancer cells in vitro

  • Kimberley Pryor
  • Phillip Stricker
  • Pamela Russell
  • David Golovsky
  • Ronald Penny
Original Article Bladder Neoplasms, Carcinoma, Transitional Cell, BCG Vaccine, Interferon, Immunotherapy

Abstract

Direct inhibitory effects of bacillus Calmette-Guérin (BCG) and interferon α2b (IFNα2b) on six human bladder carcinoma cell lines, UCRU-BL-13, UCRU-BL-17, UCRU-BL-28, 5637, T24 and J82, were studied using an in vitro proliferation assay. Effects on proliferation following exposure to BCG or IFNα2b were analysed by [3H]thymidine incorporation over 7 days. BCG had an antiproliferative effect on all bladder lines, while sensitivity to IFNα2b varied greatly, being as remarkably low as 1 U/ml for some lines. The antiproliferative effect was greatest when cells were exposed continuously to either agent, but was still evident with a limited exposure. When clinical concentrations were simulated in vitro, BCG+IFNα2b was more effective than BCG alone and as effective as a double BCG concentration. We conclude that, in addition to their immunomodulatory effects, BCG and IFNα2b directly inhibit the proliferation of human bladder cancer cells, and often at extremely low concentrations.

Key words

Bladder neoplasms Carcinoma transitional cell BCG vaccine Interferon Immunotherapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumours. J Urol 116: 180PubMedGoogle Scholar
  2. 2.
    Lamm DL, Van Der Meijden ADPM, Morales A, Brosman SA, Catalona WJ, Herr HW, Soloway MS, Steg A, Debruyne FMJ (1992) Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol 147: 596PubMedGoogle Scholar
  3. 3.
    Ratliff TL, Gillen D, Catalona WJ (1987) Requirement of a thymus dependent immune response for BCG-mediated antitumour activity. J Urol 137:155PubMedGoogle Scholar
  4. 4.
    Bohle A, Thanhauser A, Ulmer AJ, Ernst M, Flad HD, Jocham D (1993) Dissecting the immunobiological effects of bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J Urol 150: 1932PubMedGoogle Scholar
  5. 5.
    Becich MJ, Carroll S, Ratliff TL (1991) Internalization of bacille Calmette-Guérin by bladder tumour cells. J Urol 145: 1316PubMedGoogle Scholar
  6. 6.
    Akaza H, Iwasaki A, Ohtani M, Ikeda N, Niijima K, Toida I, Koiso K (1993) Expression of antitumor response: role of attachment and viability of bacillus Calmette-Guérin to bladder cancer cells. Cancer 72: 558PubMedGoogle Scholar
  7. 7.
    Kuroda K, Brown EJ, Telle B, Russell DG, Ratliff TL (1993) Characterization of the internalization of bacillus Calmette-Guérin by human bladder tumor cells. J Clin Invest 91:69PubMedGoogle Scholar
  8. 8.
    Ratliff TL (1994) Mechanism of action of intravesical BCG for superficial bladder cancer: In: BCG immunotherapy in bladder cancer. Cooperativa Libraria Editrice Universita di Padova. Padova, p 25Google Scholar
  9. 9.
    Torti FM, Shortliffe LD, Williams RD, Pitts WC, Kempson RL, Ross JC, Palmer J, Meyers F, Ferrari M, Hannigan J, Spiegel R, McWhirter K, Freiha F (1988) Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group study. J Clin Oncol 6: 476PubMedGoogle Scholar
  10. 10.
    Borden EC, Groveman DS, Nasu T, Renzikoff C, Bryan GT (1984) Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro. J Urol 132: 800PubMedGoogle Scholar
  11. 11.
    Torti FM, Lum BL (1987) Superficial bladder cancer. Risk of recurrence and potential role for interferon therapy. Cancer 59: 613PubMedGoogle Scholar
  12. 12.
    Sen GC, Lengyel P (1992) Minireview. The interferon system. J Biol Chem 267: 5017PubMedGoogle Scholar
  13. 13.
    Shuai K (1994) Interferon-activated signal transduction to the nucleus. Curr Opin Cell Biol 6: 253PubMedGoogle Scholar
  14. 14.
    Pryor K, Goddard J, Goldstein D, Stricker P, Russell P, Golovsky D, Penny R (1995) Bacillus Calmette-Guérin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing. Br J Cancer 71: 801PubMedGoogle Scholar
  15. 15.
    Russell PJ, Wass J, Lukeis R, Garson OM, Jelbart M, Wills E, Philips J, Brown J, Carrington N, Vincent PC, Raghavan D (1989) Characterization of cell lines derived from a multiply aneuploid human bladder transitional-cell carcinoma, UCRU-BL-13. Int J Cancer 44: 276PubMedGoogle Scholar
  16. 16.
    Russell PJ, Jelbart M, Wills E, Singh S, Wass J, Wotherspoon J, Raghavan D (1988) Establishment and characterization of a new human bladder cancer cell line showing features of squamous and glandular differentiation. Int J Cancer 41: 74PubMedGoogle Scholar
  17. 17.
    Russell PJ, Palavidis Z, Rozinova E, Philips J, Wills EJ, Lukeis R, Wass J, Raghavan D (1993) Characterization of a new human bladder cancer cell line, UCRU-BL-28. J Urol 150: 1038PubMedGoogle Scholar
  18. 18.
    Hawkyard SJ, Jackson AM, James K, Prescott S, Smyth JF, Chisholm GH (1992) The inhibitory effects of interferon gamma on the growth of bladder cancer cells. J Urol 147: 1399PubMedGoogle Scholar
  19. 19.
    Jakse G, Marth C, Zechner J, Daxenbichler G (1988) Antiproliferative effect of Hu-interferon-gamma in 674V and J82 bladder carcinoma cell lines. Urol Res 16: 403PubMedGoogle Scholar
  20. 20.
    Grups JW, Bange F-CH (1990) Interferon receptors on the surface of interferon-sensitive and interferon-resistant urothelial carcinomas. Urol Res 18: 119PubMedGoogle Scholar
  21. 21.
    Ucer U, Bartsch H, Scheurich P, Pfizenmaier K (1985) Biological effects of γ-interferon on human tumor cells: quantity and affinity of cell membrane receptors for γ-IFN in relation to growth inhibition and induction of HLA-DR expression. Int J Cancer 36: 103PubMedGoogle Scholar
  22. 22.
    Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF (1990) Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol 144: 1248PubMedGoogle Scholar
  23. 23.
    Bubenik J, Baresova M, Viklicky V, Jakoubkova J, Sainerova H, Donner J (1973) Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int J Cancer 11: 765PubMedGoogle Scholar
  24. 24.
    O'Toole C, Price ZH, Ohnuki Y, Unsgaard B (1978) Ultrastructure, karyology and immunology of a cell line originated from a human transitional-cell carcinoma. Br J Cancer 38: 64PubMedGoogle Scholar
  25. 25.
    Horoszewicz JS, Leong SS, Carter WA (1979) Noncycling tumor cells are sensitive targets for the antiproliferative activity of human interferon. Science 206: 1091PubMedGoogle Scholar
  26. 26.
    Jackson AM, Alexandroff AB, Fleming D, Prescott S, Chisholm GD, Carter GD, James K (1994) Bacillus Calmette-Guérin (BCG) organisms directly alter the growth of bladder tumour cells. Int J Oncol 5: 697Google Scholar
  27. 27.
    Jackson AM, James K (1994) Understanding the most successful immunotherapy for cancer. Immunologist 2: 208Google Scholar
  28. 28.
    Patard JJ, Chopin DK, Boccon-Gibod L (1993) Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer. World J Urol 11: 165PubMedGoogle Scholar
  29. 29.
    Grups JW, Frohmuller HGW (1988) Antiproliferative effects of interferons against human bladder carcinoma cell lines in vitro. Urol Int 43: 265PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • Kimberley Pryor
    • 1
  • Phillip Stricker
    • 2
  • Pamela Russell
    • 3
    • 4
  • David Golovsky
    • 2
  • Ronald Penny
    • 1
    • 4
  1. 1.Centre for ImmunologySt. Vincent's HospitalDarlinghurstAustralia
  2. 2.Department of UrologySt. Vincent's HospitalDarlinghurstAustralia
  3. 3.Gemtourinary Cancer Research Group, Oncology Research CentrePrince of Wales HospitalRandwickAustralia
  4. 4.The University of New South WalesKensingtonAustralia

Personalised recommendations